Abstract
From the past three to four decades, ecologists and scientists have exhaustively studied the effect of increased artificial light pollution at night on the ecological and physiological behavior of mammals. The Suprachiasmatic Nuclei (SCN) or master clock in the brain of mammals including humans synchronizes the physiological functions with the light: dark cycle. The prolongation of light period in the light: dark cycle disrupts the circadian rhythm of mammals causing several negative or modified physiological consequences. Changed physiological level of melatonin, an important endocrine hormone, had been identified as an important factor causing different consequences such as cancer, diabetes mellitus, metabolic disturbances, oxidative stress, and depression. The presence of artificial light at night is the demand of the era but thoughts must be given to the prevention of consequences due to artificial light pollution and ‘how much is needed’. The review paper discusses the effect of artificial light pollution on the biological clock of humans and associated negative physiological consequences. Further, the paper also briefly discusses the economics of light pollution and measures needed to prevent physiological disorders in humans.
Keywords: Artificial light, light pollution, melatonin, biological clock, circadian rhythm, cancer, obesity.
Graphical Abstract
[1]
Schernhammer ES, Schulmiester K. Melatonin and cancer risk: Does light at night compromise physiologic cancer protection by lowering serum melatonin level. Br J Cancer 2004; 90: 941-3.
[2]
Chepesuik R. Missing the dark health effects of light pollution. Environ Health Perspect 2009; 117: A20-7.
[3]
Reiter RJ, Tan DX, Barcello ES, et al. Circadian mechanism in the regulation of melatonin synthesis: Disruption with light at night and the pathophysiological consequences. J Exp Integr Med 2011; 1: 13-22.
[4]
Navara KJ, Nelson RJ. The dark side of light at night: Physiological, epidemiological and ecological consequences. J Pineal Res 2007; 43: 215-24.
[5]
Zubidat AE. Abraham Haim. Artificial light at night. A novel lifestyle risk factor for metabolic disorder and cancer morbidity. J Basic Clin Physiol Pharmacol 2017; 28(4): 295-313.
[6]
Pittendrigh CS. Temporal organization: Reflections of a Darwinian clock-watcher. Annu Rev Physiol 1993; 55: 16-54.
[7]
Stephan FK, Zucker I. Circadian rhythms in drinking behavior and locomotor activity of rats are eliminated by hypothalamic lesions. Proc Natl Acad Sci USA 1972; 69: 1583-6.
[8]
Hastings MH, Reddy AB, Maywood ES. A clockwork web: Circadian timing in brain and periphery in health and disease. Nat Rev Neurosci 2003; 4: 649-61.
[10]
Ko CH, Takahashi JS. Molecular components of the mammalian circadian clock. Hum Mol Genet 2006; 15: R271-7.
[11]
Debruyne JP. Oscillating perceptions: The ups and downs of the CLOCK protein in the mouse circadian system. J Genet 2008; 87: 437-46.
[12]
Parekh PK, McClung CA. Circadian mechanisms underlying reward-related neurophysiology and synaptic plasticity. Front Psychiatry 2016; 6: 1-11.
[13]
Eide EJ, Woolf MF, Kang H, et al. Control of mammalian circadian rhythm by CKI epsilon-regulated proteasome-mediated PER2 degradation. Mol Cell Biol 2005; 25: 2795-807.
[14]
Virshup DM, Eide EJ, Forger DB, et al. Reversible protein phosphorylation regulates circadian rhythms. Cold Spring Harb Symp Quant Biol 2007; 72: 413-20.
[15]
Honma S, Kawamoto T, Takagi Y, et al. Dec1 and Dec2 are regulators of the mammalian molecular clock. Nature 2002; 419: 841-4.
[16]
Ueda HR, Hayashi S, Chen W, et al. System level identification of transcriptional circuits underlying mammalian circadian clocks. Nat Genet 2005; 37: 187-92.
[17]
Ripperger JA, Albrecht U. REV-ERB-erating nuclear receptor functions in circadian metabolism and physiology. Cell Res 2012; 22: 1319-21.
[18]
Zhao X, Cho H, Yu RT, et al. Nuclear receptors rock around the clock. EMBO Rep 2014; 15: 518-28.
[19]
Fukuhara C, Tosini G. Peripheral circadian oscillators and theirrhythmic regulation. Front Biosci 2003; 8: d642-51.
[20]
Cuninkova L, Brown SA. Peripheral circadian oscillators: Interesting mechanisms and powerful tools. Ann N Y Acad Sci 2008; 1129: 358-70.
[21]
Dibner C, Schibler U, Albrecht U. The mammalian circadian timing system: Organization and coordination of central and peripheral clocks. Annu Rev Physiol 2010; 72: 517-49.
[22]
Brown SA, Azzi A. Peripheral circadian oscillators in mammals. Handb Exp Pharmacol 2013; 217: 45-66.
[23]
Schibler U, Gotic I, Saini C, et al. Clock-talk: Interactions between central and peripheral circadian oscillators in mammals. Cold Spring Harb Symp Quant Biol 2015; 80: 223-32.
[25]
Reiter RJ. Pineal melatonin: Cell biology of its synthesis and of its physiological interactions. Endocr Rev 1991; 12: 151-80.
[27]
Provencio I, Rodriguez IR, Jiang G, et al. A novel human opsin in the inner retina. J Neurosci 2000; 20: 600-5.
[28]
Hankins MW, Peirson SN, Foster RG. Melanopsin: An exciting photopigment. Trends Neurosci 2008; 31: 27-36.
[29]
Brainard GC, Hanifin JP, Greeson JM, et al. Action spectrum for melatonin regulation in humans: Evidence for a novel circadian photoreceptor. J Neurosci 2001; 21: 6405-12.
[30]
Berson DM, Dunn FA, Takao M. Phototransduction by ganglion cells innervating the circadian pacemaker. Science 2002; 295: 1070-3.
[31]
Erren TC, Pape HG, Reiter RJ, et al. Chronodisruption and cancer. Naturwissenschaften 2008; 95: 367-82.
[32]
Falchi F, Cinzano P, Elvidge CD, et al. Limiting the impact of light pollution on human health, environment and stellar visibility. J Environ Manage 2011; 92: 2714-22.
[33]
Aube M, Roby J, Kocifaj M. Evaluating potential spectral impacts of various artificial lights on melatonin suppression, photosynthesis, and star visibility. PLoS One 2013; 8: e67798.
[34]
West KE, Jablonski MR, Warfield B, et al. Blue light from light-emitting diodes elicits a dose dependent suppression of melatonin in humans. J Appl Physiol 2011; 110: 619-26.
[35]
Wehr TA. The durations of human melatonin secretion and sleep respond to changes in daylength (photoperiod). J Clin Endocrinol Metab 1991; 73: 1276-80.
[36]
Mazzio EA, Soliman KF. Basic concepts of epigenetics: Impact of environmental signals on gene expression. Epigenetics 2012; 7: 119-30.
[37]
Deaton AM, Bird A. CpG islands and the regulation of transcription. Genes Dev 2011; 25: 1010-22.
[38]
Jones PA. Functions of DNA methylation: Islands, start sites, gene bodies and beyond. Nat Rev Genet 2012; 13: 484-92.
[39]
Du J, Johnson LM, Jacobsen SE, et al. DNA methylation pathways and their crosstalk with histone methylation. Nat Rev Mol Cell Biol 2015; 16: 519-32.
[40]
Moore LD, Le T, Fan G. DNA methylation and its basic function. Neuropsychopharmacology 2013; 38: 23-38.
[42]
Smith CJ, Ryckman KK. Epigenetic and developmental influences on the risk of obesity, diabetes and metabolic syndrome. Diabetes Metab Syndr Obes 2015; 8: 295-302.
[43]
Martinez-Cardus A, Vizoso M, Moran S, et al. Epigenetic mechanisms involved in melanoma pathogenesis and chemoresistance. Ann Transl Med 2015; 3: 209.
[44]
Uth K, Sleigh R. Deregulation of the circadian clock constitutes a significant factor in tumorigenesis: A clockwork cancer. Part II. In vivo studies. Biotechnol Equip 2014; 28: 379-86.
[45]
Sotak M, Sumova A, Pacha J. Cross-talk between the circadian clock and the cell cycle in cancer. Ann Med 2014; 46: 221-32.
[46]
Gery S, Komatsu N, Baldjyan L, et al. The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell 2006; 22: 375-82.
[47]
Xiang S, Coffelt SB, Mao L, et al. Period-2: A tumor suppressor gene in breast cancer. J Circadian Rhythms 2008; 6: 4.
[48]
Gery S, Virk RK, Chumakov K, et al. The clock gene Per2 links the circadian system to the estrogen receptor. Oncogene 2007; 26: 7916-20.
[49]
Zienolddiny S, Haugen A, Lie JA, Kjuus H, Anmarkrud KH, Kjarheim K. Analysis of polymorphisms in the circadian related genes and breast cancer risk in Norwegian nurses working night shifts. Breast Cancer Res 2013; 15: R53-68.
[50]
Rafnsson V, Tulinius H, Jonasson JG, et al. Risk of breast cancer in female flight attendants: A population-based study (Iceland). Cancer Causes Control 2001; 12: 95-101.
[51]
Megdal SP, Kroenke CN, Laden F, et al. Night shift work and breast cancer: A systemic review and meta-analysis. Eur J Cancer 2005; 2023-32.
[52]
He C, Anand ST, Ebell MH, et al. Circadian disrupting exposures and breast cancer risk: A meta-analysis. Int Arch Occup Environ Health 2015; 88: 533-47.
[53]
Hansen J. Increased breast cancer risk among women who work predominantly at night. Epidemiology 2001; 12(1): 74-7.
[54]
Kloog I, Haim A, Stevens RG, et al. Light at night co-distributes with incident breast but not lung cancer in the female population of Israel. Chronobiol Int 2008; 25: 65-81.
[55]
O’Leary ES, Schoenfeld ER, Stevens RG, et al. Electromagnetic fields and breast cancer on long island study group. Shift work, light at night and breast cancer on Long Island, New York. Am J Epidemiol 2006; 164: 358-66.
[56]
Li Q, Zheng T, Holford TR, et al. Light at night and breast cancer risk: Results from a population-based case-control study in Connecticut, USA. Cancer Causes Control 2010; 21: 2281-5.
[57]
Kloog I, Portnov BA, Rennert HS, et al. Does the modern urbanized sleeping habitat pose a breast cancer risk? Chronobiol Int 2011; 28: 76-80.
[58]
Hurley S, Goldberg D, Nelson D, et al. Light at night and breast cancer risk among California teachers. Epidemiology 2014; 25: 697-706.
[59]
Keshet-Sitton A, Or-Chen K, Yitzhak S, et al. Can avoiding light at night reduce the risk of breast cancer? Integr Cancer Ther 2016; 15: 145-52.
[60]
Wu J, Dauchy RT, Tirrell PC, et al. Light at night activates IGF-1R/PDK1 signaling and accelerates tumor growth in human breast cancer xenografts. Cancer Res 2011; 71: 2622-31.
[61]
Blask DE, Dauchy RT, Sauer LA, et al. Growth and fatty acid metabolism of human breast cancer (MCF-7) xenografts in nude rats: impact of constant light-induced nocturnal melatonin suppression. Breast Cancer Res Treat 2003; 79: 313-20.
[62]
Dauchy RT, Sauer LA, Blask DE, et al. Light contamination during the dark phase in “photoperiodically controlled” animal rooms: Effect on tumor growth and metabolism in rats. Lab Anim Sci 1997; 47: 511-8.
[63]
Schwimmer H, Metzer A, Pilosof Y, et al. Light at night and melatonin have opposite effects on breast cancer tumors in mice assessed by growth rates and global DNA methylation. Chronobiol Int 2014; 31: 144-50.
[64]
Zubidat AE, Fares B, Faras F, et al. Melatonin functioning through DNA methylation to constrict breast cancer growth accelerated by blue LED light at night in 4T1 tumor bearing mice. Gratis J Cancer Biol Ther 2015; 1: 57-73.
[65]
Blask DE, Brainard GC, Dauchy RT, et al. Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of breast cancer xenografts in nude rats. Cancer Res 2005; 65: 11174-84.
[66]
Sanchez-Barcelo E, Cos S, Mediavilla D, et al. Melatonin-estrogen interactions in breast cancer. J Pineal Res 2005; 38: 217-22.
[67]
Radpour R, Kohler C, Haghighi MM, et al. Methylation profiles of 22 candidate genes in breast cancer using high-throughput MALDI-TOF mass array. Oncogene 2009; 28: 2969-78.
[68]
Bediaga NG, Acha-Sagredo A, Guerra I, et al. DNA methylation epigenotypes in breast cancer molecular subtypes. Breast Cancer Res 2010; 12: R77.
[69]
Wong EM, Southey MC, Fox SB, et al. Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer. Cancer Prev Res (Phila) 2011; 4: 23-33.
[70]
Stefansson OA, Esteller M. Epigenetic modifications in breast cancer and their role in personalized medicine. Am J Pathol 2013; 183: 1052-63.
[71]
Xiang TX, Yuan Y, Li LL, et al. Aberrant promoter CpG methylation and its translational applications in breast cancer. Chin J Cancer 2013; 32: 12-20.
[72]
Hoffman AE, Yi CH, Zheng T, et al. CLOCK in breast tumorigenesis: Genetic, epigenetic, and transcriptional profiling analyses. Cancer Res 2010; 70: 1459-68.
[73]
Hoffman AE, Zheng T, Yi CH, et al. The core circadian gene Cryptochrome 2 influences breast cancer risk, possibly by mediating hormone signaling. Cancer Prev Res (Phila) 2010; 3: 539-48.
[74]
Chen ST, Choo KB, Hou MF, et al. Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis 2005; 26: 1241-6.
[75]
Shih MC, Yeh KT, Tang KP, et al. Promoter methylation in circadian genes of endometrial cancers detected by methylation-specific PCR. Mol Carcinog 2006; 45: 732-40.
[76]
Bhatti P, Zhang Y, Song X, et al. Nightshift work and genome–wide DNA methylation. Chronobiol Int 2015; 32: 103-12.
[77]
Kubo T, Ozasa K, Mikami E, et al. Prospective cohort study of the risk of prostate cancer among rotating-shift workers: Findings from the Japan collaborative cohort study. Am J Epidemiol 2006; 164: 549-55.
[79]
Kim YK, Lee E, Kim YJ, et al. The association between artificial light at night and prostate cancer in Gwangju city and south Jeolla province of South Korea. Chronobiol Int 2016; 34(2): 1-9.
[80]
Saenz AG, Miguel AS, Espinosa A, et al. Evaluating the association between artificial light at night exposure and breast and prostate cancer risk in Spain (MCC Spain study). Environ Health Perspect 2018; 126(4): 1-11.
[81]
Xin Z, Jiang S, Jiang P, et al. Melatonin as a treatment for gastrointestinal cancer: A review. J Pineal Res 2015; 58: 375-87.
[82]
Naggar RA, Shirirn A. Artificial light at night and cancer: Global study. Asian Pac J Cancer Prev 2016; 17(10): 4661-4.
[83]
Nelson RJ, Drazen DL. Melatonin mediates seasonal adjustments in immune function. Reprod Nutr Dev 1999; 39: 383-98.
[84]
Rodriguez MI, Carretero M, Escames G, et al. Chronic melatonin treatment prevents age-dependent cardiac mitochondrial dysfunction in senescence-accelerated mice. Free Radic Res 2007; 41: 15-24.
[85]
Haus E, Smolensky M. Biological clocks and shift work: Circadian dysregulation and potential long-term effects. Cancer Causes Control 2006; 17: 489-500.
[86]
Yonis M, Haim A, Zubidat E. Altered metabolic and hormonal responses in male rats exposed to acute bright light-at-night associated with global DNA hypo-methylation. J Photochem Photobiol B Biol 2019; 194: 107-18.
[87]
Fruhbeck G, Becerril S, Sainz N, et al. BAT: A new target for human obesity? Trends Pharmacol Sci 2009; 30: 387-96.
[88]
Tan DX, Manchester LC, Fuentes-Broto L, et al. Significance and application of melatonin in the regulation of brown adipose tissue metabolism: Relation to human obesity. Obes Rev 2011; 12: 167-88.
[89]
Griggio MA. Thermogenic mechanisms in cold-acclimated animals. Braz J Med Biol Res 1988; 21: 171-6.
[90]
Terron MP, Delgado-Adamez J, Pariente JA, et al. Melatonin reduces body weight gain and increases nocturnal activity in male Wistar rats. Physiol Behav 2013; 118: 8-13.
[91]
Hidayat M, Maha Y, Wasim H. Effect of melatonin on serum glucose and body weight in streptozotocin induced diabetes in albino rats. J Ayub Med Coll Abbottabad 2015; 27: 274-6.
[92]
Bartness TJ, Wade GN. Photoperiodic control of seasonal body weight cycles in hamsters. Neurosci Biobehav Rev 1985; 9: 599-612.
[93]
Fonken LK, Workman JL, Walton JC, et al. Light at night increases body mass by shifting the time of food intake. PNAS 2010; 107(43): 18664-9.
[94]
Wyse CA, Selman C, Page MM, et al. Circadian desynchrony and metabolic dysfunction; did light pollution make us fat. Med Hypotheses 2011; 77(6): 1139-44.
[95]
Patel SR, Hu FB. Short sleep duration and weight gain: A systematic review. Obesity 2008; 16(3): 643-53.
[96]
Dominguez RA, Abreu GP, Sanchez SJJ, et al. Melatonin and circadian biology in human cardiovascular disease. J Pineal Res 2010; 49: 14-22.
[97]
Dominguez RA, Abreu GP, Reiter RJ. Clinical aspects of melatonin in the acute coronary syndrome. Curr Vasc Pharmacol 2009; 7: 367-73.
[98]
Reiter RJ, Tan DX, Paredes SD, et al. Beneficial effects of melatonin in cardiovascular disease. Ann Med 2010; 42: 276-85.
[99]
Sun H, Gusdon AM, Qu S. Effects of melatonin on cardiovascular diseases: Progress in the past year. Curr Opin Lipidol 2016; 27(4): 408-13.
[100]
Champney TH, Brainard GC, Richardson BA, et al. Experimentally-induced diabetes reduces nocturnal pineal melatonin content in the Syrian hamster. Comp Biochem Physiol Part A Physiol 1983; 76(1): 199-201.
[102]
McMullan CJ, Schernhammer ES, Rimm EB, et al. Melatonin secretion and the incidence of Type 2 diabetes. JAMA 2013; 309(13): 1388-96.
[103]
Maung SC, Sara AE, Chapman C, et al. Sleep disorders and chronic kidney disease. World J Nephrol 2016; 5(3): 224-32.
[104]
Mehta R, Drawz PE. Is nocturnal blood pressure reduction the secret to reducing the rate of progression of hypertensive chronic kidney disease. Curr Hypertens Rep 2011; 13: 378-85.
[105]
Harb F, Hidalgo MP, Martau B. Lack of exposure to natural light in the workspace is associated with physiological, sleep and depressive symptoms. Chronobiol Int 2015; 32(3): 368-75.
[106]
Min JY, Min KB. Outdoor light at night and the prevalence of depressive symptoms and suicidal behaviors: A cross-sectional study in a nationally representative sample of Korean adults. J Affect Disord 2018; 227: 199-205.
[107]
Rodriguez C, Mayo JC, Sainz RM, et al. Regulation of antioxidant enzymes: A significant role for melatonin. J Pineal Res 2004; 36: 1-9.
[108]
Reiter RJ, Tan DX, Osuna C, et al. Actions of melatonin in the reduction of oxidative stress. J Biomed Sci 2000; 7: 444-58.
[109]
Baydas G, Ercel E, Canatan H, et al. Effect of melatonin on oxidative status of rat brain, liver, and kidney tissues under constant light exposure. Cell Biochem Funct 2001; 19: 37-41.
[110]
Tunez I, Munoz M, Feijoo M, et al. Melatonin effect on renal oxidative stress under constant light exposure. Cell Biochem Funct 2003; 21: 35-40.
[111]
Urata Y, Honma S, Goto S, et al. Melatonin induces gamma-glutamyl cysteine synthetase mediated by activator protein-1 in human vascular endothelial cells. Free Radic Biol Med 1999; 27: 838-47.
[112]
Tan DX, Manchester LC, Terron MP, et al. One molecule, many derivatives: A never-ending interaction with melatonin with reactive oxygen and nitrogen species. J Pineal Res 2007; 42: 28-42.
[113]
Moore CB, Siopes TD. Effects of lighting conditions and melatonin supplementation on the cellular and humoral immune responses in Japanese quail Coturnix japonica. Gen Comp Endocrinol 2000; 119: 95-104.
[114]
Kirby JD, Froman DP. Research note: Evaluation of humoral and delayed hypersensitivity responses in cockerals reared under constant light or a twelve hour light: Twelve hour dark photoperiod. Poult Sci 1991; 70: 2375-8.
[115]
Oishi K, Shibusawa K, Kakazu H, et al. Extended light exposure suppresses nocturnal increases in cytotoxic activity of splenic natural killer cells in rats. Biol Rhythm Res 2006; 37: 21-35.
[116]
Vaughan MK, Hubbard GB, Champney TH, et al. Splenic hypertrophy and extramedullary hematopoiesis induced in male Syrian hamsters by short photoperiod or melatonin injections and reversed by melatonin pellets or pinealectomy. Am J Anat 1987; 179: 131-6.
[117]
Carrillo-Vico A, Guerrero JM, Lardone PJ, et al. A review of the multiple actions of melatonin on the immune system. Endocrine 2005; 27: 189-200.
[118]
Cinzano P, Falchi F, Elvidge CD. The first world atlas of the artificial night sky brightness. Month Notice Royal Astronom Soc 2001; 328: 689-707.
[119]
Gallaway T, Olsen RN, Mitchell DM. The economics of global light pollution. Ecol Econ 2010; 69: 658-65.
[120]
Elvidge CD, Baugh KE, Kihn EA, et al. Mapping of city lights using DMSP operational line scan system data. Photogramm Eng Remote Sensing 1997; 63: 727-34.
[121]
Elvidge CD, Imhoff ML, Baugh KE, et al. Night time lights of the world: 1994-95. ISPRS J Photogramm Remote Sens 2001; 56: 81-99.
[122]
Mayhew C, Simmon R. NASA GSFC. “Earth's City
Lights”. Data courtesy Marc Im hoff of NASA GSFC and
Christopher Elvidge of NOAA NGDC 2000.
[123]
Cinzano P, Falchi WF, Elvidge CD, et al. The artificial night sky brightness mapped from DMSP satellite Operational Linescan System measurements. Monthly Notices of the Royal Astronomical Society 2000; 318: 641-57.
Article Metrics
23
6